Printed From BioPortfolio.com

Roche’s Tecentriq approved for funding in UK in bladder cancer

07:10 EDT 1 Nov 2017 | Pharmafile

In a rare spot of good news for Tecentriq (atezolizumab), after a turbulent period, Roche’s drug has been given the nod by NICE to be funded through the Cancer Drug Fund (CDF).

Tecentriq has been approved to treat patients with bladder cancer who have not previously been treated and are unsuitable for cisplatin-based chemotherapy. The approval means that approximately half of all patients with metastatic bladder cancer could be eligible for treatment with Tecentriq.

Original Article: Roche’s Tecentriq approved for funding in UK in bladder cancer

More From BioPortfolio on "Roche’s Tecentriq approved for funding in UK in bladder cancer"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches